Copyright
©The Author(s) 2016.
World J Gastroenterol. Apr 7, 2016; 22(13): 3632-3643
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Table 2 Survival period and survival rate in different groups
| Mean overall survival (mo) | 3-mo survival rate | 6-mo survival rate | 12-mo survival rate | 24-mo survival rate | |
| TACE administration | 10.39 | 94.1% | 85.9% | 51.5% | 0.0% |
| TACE subgroup | 10.22 | 93.8% | 86.7% | 43.9% | 0.0% |
| TACE-sorafenib subgroup | 10.52 | 95.3% | 83.3% | 53.8% | 0.0% |
| Liver resection + TACE | 4.13 | 60.3% | 22.2% | 0.0% | 0.0% |
| Targeted therapy of sorafenib | 3.54 | 50.9% | 29.5% | 0.0% | 0.0% |
| Palliate treatment | 2.82 | 55.0% | 0.0% | 0.0% | 0.0% |
- Citation: Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016; 22(13): 3632-3643
- URL: https://www.wjgnet.com/1007-9327/full/v22/i13/3632.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i13.3632